This indicates that GSK-3β inhibitor can be used as an autophagy-targeted drug, and autophagy blockade has the potential to be an effective interventional strategy for addressing cancer progression and overcoming therapeutic resistance in addition to existing treatment. This evidence concerns the gene GSK3B and cancer.